Health
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid Tumors Receiving Cisplatin ChemotherapyRESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Tampa General Hospital (TGH) Cancer Institute is initiating a study
About this update from Fennec Pharmaceuticals Inc.
[{"type":"image","alt":"Fennec Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Fennec Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":131,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/2efcdbca67a3a46e7d58086ce409299f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TjrO4_RDcmN0kDygynnR1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2efcdbca67a3a46e7d58086ce409299f","width":131,"height":74}},"lazy":false},{"type":"text","content":"Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid Tumors Receiving Cisplatin Chemotherapy","length":259,"tagName":"p"},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Tampa General Hospital (TGH) Cancer Institute is initiating a study evaluating the real-world clinical utility of sodium thiosulfate injection (PEDMARK®) in reducing the risk of ototoxicity in Adolescent and Young Adult (AYA) and adult cancer patients receiving cisplatin-based treatment.","length":467,"tagName":"p"},{"type":"text","content":"“The TGH Cancer Institute, in collaboration with the USF Health Morsani College of Medicine, is committed to better understanding and advancing otoprotective strategies aimed at preserving auditory function in patients receiving cisplatin chemotherapy,” said Gene A. Wetzstein, PharmD, BCOP, Director of Supportive Care Research & Scientific Affairs at the TGH Cancer Institute and principal investigator of the initiative. “This evaluation will examine real-world clinical data and audiology monitoring that will help inform future clinical research and quality efforts in assessing, preventing and managing ototoxicity.”","length":626,"tagName":"p"},{"type":"text","content":"PEDMARK® is currently approved for pediatric patients one month of age and older with localized non-metastatic solid tumors and is also recognized by the National Comprehensive Cancer Network with a 2A recommendation for use in AYA patients.","length":241,"tagName":"p"},{"type":"text","content":"“Real-wor...